京新藥業(002020.SZ):“沙美特羅替卡鬆吸入粉霧劑”獲批臨牀試驗
格隆匯 9 月 17日丨京新藥業(002020.SZ)公佈,近日,公司控股子公司杭州京瑞醫藥科技有限公司(“杭州京瑞”)獲得國家藥品監督管理局下發的《藥物臨牀試驗批准通知書》,其提交的“沙美特羅替卡鬆吸入粉霧劑”獲藥物臨牀試驗批准通知書。
沙美特羅替卡鬆吸入粉霧劑主要用於可逆的氣道阻塞性氣道疾病的規律治療,包括成人和兒童哮喘,包括接受有效維持劑量的長效β受體激動劑和吸入型糖皮質激素治療的患者;目前使用吸入型糖皮質激素治療但仍有症狀的患者。沙美特羅替卡鬆吸入粉霧劑由葛蘭素史克公司原研開發,杭州京瑞首次提交沙美特羅替卡鬆吸入粉霧劑註冊獲得受理時間為2019年05月,受理號為JXHS1900073、JXHS1900074、JXHS1900075。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.